Thursday, July 27, 2023 Daily Archives

Bioprocessing blighted by ‘deteriorating funding,’ China, and post-COVID, say Danaher and Thermo

A dry up of biotech funding and a slowdown in China are among the macroeconomic issues affecting growth in the bioprocessing space, say both Thermo Fisher and Danaher. With reporting season underway, Danaher Corporation described a “softer demand in bioprocessing” affecting Q2 numbers. The firm owns Cytiva, which recently absorbed fellow bioprocess vendor Pall, and reported a 17% decline in sales for the quarter compared to last year. Danaher does not disclose the monetary amounts across its divisions. “Larger customers…

Biovian forks out $55m to expand Finland facility

The decision to invest and expand manufacturing capacity is driven by the increasing demand for biologics and gene therapies, says firm. According to Finnish contract development manufacturing organization (CDMO) Biovian, the expansion of its manufacturing plant in Turku, Finland, will enable the firm to take on larger-scale viral vector, microbial protein projects, and concurrent production by scaling up manufacturing capacity and flexibility. The 69,000 square foot will include various equipment and technologies to support the advancement, production, and testing of…